Vir biotechnology focuses on hepatitis. Their main drug Tobevibart for Hepatitis D looks promising and got awarded by FDA. Topline results expected 2026. However for Hepatitis B the trial looks not promising. They have a very good cash position. Since other pipeline drugs are very early in development they rely on their hepatitis D candidate.
Balance Sheet
Q1 25. Units in million except price.
| price | 5.25 |
| mc | 682 |
| cash | 790 |
| debt | 120 |
| ev | 10 |
| shares | 138 |
| aPIC | 1926 |
| ad | 880 |
Income Statement
Units in million.
| 2025 | 2024 | |
|---|---|---|
| rev | 3 | 56 |
| rnd | 118 | 100 |
| sga | 24 | 36 |
| net loss | -120 | -65 |
| FCF | -80 | -111 |
| shares | 137.4 | 135.2 |
Pipeline
| Pipeline | Phase | Indication | Mechanism of Action | Upcoming Catalyst |
|---|---|---|---|---|
| Tobevibart + Elebsiran | Phase 3 | Chronic Hepatitis D (CHD) | Anti-HBs monoclonal antibody + siRNA | ECLIPSE Phase 3 initiated – Topline H1 2025 |
| Tobevibart + Elebsiran ± IFNα | Phase 2 | Chronic Hepatitis B (CHB) | Anti-HBs monoclonal antibody + siRNA ± immune stimulation | MARCH Part B – 24-week data Q2 2025 (EASL) |
| Broadly neutralizing antibody (HIV) | Preclinical / IND-enabling | HIV prevention or treatment | Antibody-based | In development with Gates Foundation |
| VIR-5818 | Phase 1 | HER2+ solid tumors | Dual-masked HER2xCD3 T-cell engager | Positive early Phase 1 data |
| VIR-5500 | Phase 1 | Metastatic castration-resistant prostate cancer (mCRPC) | Dual-masked PSMAxCD3 T-cell engager | PSA50 response in 58% – further data expected |
| VIR-5525 | Planned Phase 1 | EGFR+ solid tumors | Dual-masked EGFRxCD3 T-cell engager | First-in-human study expected H1 2025 |
| Multiple masked TCEs (dAIsY™ platform) | Preclinical | Various solid tumors | Dual-masking + PRO-XTEN™ | Preclinical development |
| Influenza A candidate | Preclinical | Influenza A | Neutralizing monoclonal antibody | Research phase |
| RSV/MPV candidate | Preclinical | RSV and/or MPV | Neutralizing antibody | Research phase |
| HPV candidate | Preclinical | Human papillomavirus | Antibody-based | Research phase |